About Connect Biopharma Holdings Ltd
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.connectbiopharm.com
Frequently Asked Questions
What is the 52-week range for CNTB?
The 52-week high is $3.82 and the 52-week low is $0.886.
What is the P/E ratio for CNTB?
The P/E ratio data is currently unavailable.
What is the dividend yield for CNTB?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -165.41%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -1824.65%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.83.
Analyst Recommendation Trends
Wall Street analyst consensus for CNTB over the last few months:
Latest CNTB News
HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $7 price target.
Top movers analysis one hour before the close of the markets on 2026-09-30: top gainers and losers in today's session.
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
Discover the most active stocks in Wednesday's session.
Let's dive into the action on the US markets on Wednesday. Here are the most active stocks that are driving the market today.
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 9.7% to $13.09 during Wednesday's after-market session. The company's market cap stands at $1.0 billion. Filana Therapeutics (NASDAQ:FLNA) shares rose
Let's take a look at the stocks that are in motion in today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session.
Crude Oil Rises Over 1%; Conagra Brands Earnings Top Views
U.S. stocks mixed: Dow fell over 200 points, while Nasdaq and S&P 500 rose; inflation cooled and Q2 GDP was revised higher.
Connect Biopharma Reports Positive Phase 2 Rademikibart COPD Data, Plans FDA Talks on Phase 3 Program
Rademikibart significantly reduced treatment failure and new moderate-to-severe COPD exacerbations in the Seabreeze STAT study, while Connect Biopharma said it plans to discuss a Phase 3 registrational program with the FDA. Key Investor TakeawaysConnect Biopharma (NASDAQ:CNTB) reported positive preliminary topline data from the 159-patient Phase 2 Seabreeze STAT COPD trial of rademikibart.
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations - Slideshow
2026-09-30. The following slide deck was published by Connect Biopharma Holdings Limited in conjunction with this event.
Which stocks are gapping on Wednesday?
In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.
Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy
Connect Biopharma reports positive Phase 2 results for rademikibart, showing an 81% reduction in COPD treatment failure and high safety.
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations Transcript
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations September 30,...
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 147.1% to $0.18 during Wednesday's regular session. Tenon Medical (NASDAQ:TNON) stock increased by 47.25% to $4.02. The market value of their
BTIG Maintains Buy on Connect Biopharma Hldgs, Lowers Price Target to $5
BTIG analyst Julian Harrison maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and lowers the price target from $10 to $5.
Wednesday's pre-market session: top gainers and losers
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
– Rademikibart significantly reduced the rate of treatment failure compared to placebo through one month by 81% (p=0.0122) – – Rademikibart significantly reduced the rate of new moderate to severe COPD exacerbations through one month by 85% (p=0.030) – – Rademikibart significantly reduced the rate of hospitalizations or emergency department visits for new acute COPD exacerbations by 100% (p=0.0137) – – Rademikibart was well tolerated in COPD patients experiencing an acute exacerbation with a low
Nasdaq Gains Over 100 Points; Jabil Posts Upbeat Earnings
U.S. stocks rose, led by tech, as Jabil beat Q4 estimates and raised FY2027 guidance; oil and gold also climbed.
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 106.0% to $0.15 during Wednesday's pre-market session. Connect Biopharma Hldgs (NASDAQ:CNTB) stock increased by 79.43% to $1.78. The market value of
Connect Biopharma Announces Topline Results From Its Global Phase 2 Study Evaluating Rademikibart As An Add-on Treatment For Acute Exacerbations In Adult Participants With Chronic Obstructive Pulmonary Disease And Type 2 Inflammation; Rademikibart Significantly Reduced The Rate Of Treatment Failure Compared To Placebo Through One Month By 81%; Rademikibart Significantly Reduced The Rate Of New Moderate To Severe COPD Exacerbations Through One Month By 85%
Key topline results include:Rademikibart significantly reduced the rate of treatment failure by 81% through Week 4 compared to placebo (p=0.0122)Rademikibart significantly reduced the rate of new moderate to severe COPD
Connect Biopharma (CNTB) Misses Key Asthma Trial Goal. Can its Drug Still Move Forward?
Connect Biopharma Holdings Limited (NASDAQ:CNTB) reported mixed preliminary results on September 15 from its Phase 2 Seabreeze STAT asthma study. Rademikibart produced a numerical 66% reduction in treatment failure over 28 days versus placebo, but the primary endpoint missed statistical significance, with p=0.153. Connect Biopharma Holdings Limited (NASDAQ:CNTB) also reported a lung-function benefit on a […]
Oppenheimer Maintains Outperform on Connect Biopharma Hldgs, Lowers Price Target to $5
Oppenheimer analyst Mazahir Alimohamed maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Outperform and lowers the price target from $8 to $5.
Canaccord Genuity Maintains Buy on Connect Biopharma Hldgs, Lowers Price Target to $6
Canaccord Genuity analyst Edward Nash maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and lowers the price target from $7 to $6.
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations Transcript
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations September 15, 2026 8:00 AM...
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations - Slideshow
2026-09-16. The following slide deck was published by Connect Biopharma Holdings Limited in conjunction with this event.
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Keep an eye on the top gainers and losers in Tuesday's session.
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Connect Biopharma Rademikibart Phase 2 Data Shows Lung Function Improvement but Primary Endpoint Misses Significance
Connect Biopharma reported a statistically significant improvement in lung function in its Phase 2 Seabreeze STAT asthma trial, while a 66% reduction in treatment failures did not reach statistical significance. Key Investor TakeawaysConnect Biopharma (NASDAQ:CNTB) said rademikibart produced a statistically significant 130 mL placebo-adjusted improvement in post-bronchodilator FEV1 at Day 7, with a p-value of 0.
Let's uncover which stocks are experiencing notable gaps during today's session.
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers PDS Biotechnology (NASDAQ:PDSB) shares rose 63.7% to $0.65 during Tuesday's regular session. The market value of their outstanding shares is at $22.3 million. DataMEDS AI (NASDAQ:MEDS) shares increased by
What's going on in today's pre-market session
The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
BTIG Reiterates Buy on Connect Biopharma Hldgs, Maintains $10 Price Target
BTIG analyst Julian Harrison reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $10 price target.
Why Is Connect Biopharma Stock Trading Lower on Tuesday?
Connect Biopharma asthma drug rademikibart misses primary endpoint but shows improved lung function and a favorable safety profile.
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation
– Rademikibart meaningfully reduced the rate of treatment failure at 28 days by 66% compared to placebo – –Rademikibart produced a rapid, statistically significant improvement in lung function at Day 7 compared to placebo – – Rademikibart was well tolerated in asthma patients experiencing an acute exacerbation with a low incidence of adverse events– – Data from Seabreeze STAT COPD study of rademikibart will be available later this month after which Connect plans to engage with the U.S. Food and
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 39.3% to $1.56 during Tuesday's pre-market session. The company's market cap stands at $1.1 million. As per the press release, H1 earnings
Connect Biopharma's Interim Topline Data from Phase 2 Study Shows Rademikibart Reduced Treatment Failure Rate at 28 Days by 66% and Improved Lung Function Vs. Placebo
Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Basel Medical Group (NASDAQ:BMGL) shares moved upwards by 59.8% to $7.32 during Monday's regular session. Scinai Immunotherapeutics (NASDAQ:SCNI) stock increased by 45.18% to $2.41. The company's
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-30 | Xanthopoulos Kleanthis Gabriel | +5,000 | - | - |
| 2026-09-30 | LIU JEAN I | +8,984 | - | - |
| 2026-06-30 | Xanthopoulos Kleanthis Gabriel | +3,738 | - | - |
| 2026-06-30 | LIU JEAN I | +6,718 | - | - |
| 2026-05-29 | Huang James | +150,000 | $2.4774 | $371,610 |
| 2026-03-31 | Xanthopoulos Kleanthis Gabriel | +2,816 | - | - |
| 2026-03-31 | LIU JEAN I | +5,061 | - | - |
| 2026-03-31 | Huang James | +1,160,000 | $3.45 | $4,002,000 |